Literature DB >> 24904116

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.

David O'Connor1, Jessica Bate2, Rachel Wade3, Rachel Clack3, Sunita Dhir4, Rachael Hough5, Ajay Vora6, Nick Goulden7, Sujith Samarasinghe7.   

Abstract

Although infection is the major cause of treatment-related mortality (TRM) in childhood acute lymphoblastic leukemia, factors associated with infection-related mortality (IRM) are poorly understood. To address this, we report an analysis of all 75 cases of IRM in the United Kingdom Childhood Acute Lymphoblastic Leukaemia Randomised Trial 2003 (UKALL 2003). The 5-year cumulative incidence of IRM was 2.4% (95% confidence interval [CI], 1.9%-3.0%), accounting for 75 (30%) of 249 trial deaths and 75 (64%) of 117 TRM deaths. Risk for IRM as a proportion of TRM was greater in induction than other phases (77% vs 56%; P = .02). Sixty-eight percent of cases were associated with bacterial infection (64% Gram-negative) and 20% with fungal infection. Down syndrome was the most significant risk factor for IRM (odds ratio [OR], 12.08; 95% CI, 6.54-22.32; P < .0001). In addition, there was a trend toward increased IRM in girls (OR, 1.63; 95% CI, 1.02-2.61; P = .04), as well as increasing treatment intensity (regimen B vs A: OR, 2.11 [95% CI, 1.24-3.60]; regimen C vs A: OR, 1.41 [95% CI, 0.76-2.62]; P = .02). Importantly, patients with Down syndrome were at significantly higher risk for IRM during maintenance (P = .048). Our results confirm Down syndrome as a major risk factor for IRM. Enhanced supportive care and prophylactic antibiotics should be considered in high-risk patient groups and during periods of increased risk. This study was registered at http://www.controlled-trials.com/ as #ISRCTN07355119.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24904116     DOI: 10.1182/blood-2014-03-560847

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia.

Authors:  Weili Sun; Etan Orgel; Jemily Malvar; Richard Sposto; Jennifer J Wilkes; Rebecca Gardner; Vanessa P Tolbert; Alison Smith; Minjun Hur; Jill Hoffman; Susan R Rheingold; Michael J Burke; Alan S Wayne
Journal:  Pediatr Blood Cancer       Date:  2016-07-20       Impact factor: 3.167

2.  Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.

Authors:  Franziska Schramm; Udo Zur Stadt; Martin Zimmermann; Norbert Jorch; Arnulf Pekrun; Arndt Borkhardt; Thomas Imschweiler; Holger Christiansen; Jörg Faber; Irene Schmid; Tobias Feuchtinger; Gerhard Beron; Monique L den Boer; Rob Pieters; Martin A Horstmann; Gritta E Janka-Schaub; Gabriele Escherich
Journal:  Blood Adv       Date:  2019-11-26

3.  Cost-effectiveness of levofloxacin prophylaxis against bacterial infection in pediatric patients with acute myeloid leukemia.

Authors:  Meghan McCormick; Erika Friehling; Ramasubramanian Kalpatthi; Nalyn Siripong; Kenneth Smith
Journal:  Pediatr Blood Cancer       Date:  2020-07-25       Impact factor: 3.167

4.  Infection-related complications during treatment for childhood acute lymphoblastic leukemia.

Authors:  H Inaba; D Pei; J Wolf; S C Howard; R T Hayden; M Go; O Varechtchouk; T Hahn; J Buaboonnam; M L Metzger; J E Rubnitz; R C Ribeiro; J T Sandlund; S Jeha; C Cheng; W E Evans; M V Relling; C-H Pui
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

5.  First do no harm: infectious deaths in pediatric ALL.

Authors:  Karen R Rabin
Journal:  Blood       Date:  2014-08-14       Impact factor: 22.113

6.  Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States.

Authors:  Elizabeth G Salazar; Yimei Li; Brian T Fisher; Susan R Rheingold; Julie Fitzgerald; Alix E Seif; Yuan-Shung Huang; Rochelle Bagatell; Richard Aplenc
Journal:  Br J Haematol       Date:  2016-05-10       Impact factor: 6.998

7.  Impact of genetic polymorphisms determining leukocyte/neutrophil count on chemotherapy toxicity.

Authors:  S J Glisovic; Y D Pastore; V Gagne; M Plesa; C Laverdière; J M Leclerc; D Sinnett; M Krajinovic
Journal:  Pharmacogenomics J       Date:  2017-05-23       Impact factor: 3.550

Review 8.  Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment).

Authors:  Rachael Hough; Ajay Vora
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

9.  Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.

Authors:  Yousif Matloub; Karen R Rabin; Lingyun Ji; Meenakshi Devidas; Johann Hitzler; Xinxin Xu; Bruce C Bostrom; Linda C Stork; Naomi Winick; Julie M Gastier-Foster; Nyla A Heerema; Eileen Stonerock; William L Carroll; Stephen P Hunger; Paul S Gaynon
Journal:  Blood Adv       Date:  2019-06-11

Review 10.  Fungal infections in children with haematologic malignancies and stem cell transplant recipients.

Authors:  William R Otto; Abby M Green
Journal:  Br J Haematol       Date:  2020-03-11       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.